Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted) (2021 - 2025)
Heron Therapeutics (HRTX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.01 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 150.0% year-over-year to -$0.01, compared with a TTM value of -$0.12 through Dec 2025, down 33.33%, and an annual FY2025 reading of -$0.12, down 33.33% over the prior year.
- EPS (Weighted Average and Diluted) was -$0.01 for Q4 2025 at Heron Therapeutics, up from -$0.1 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.02 in Q4 2024 and bottomed at -$0.63 in Q1 2022.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.23, with a median of -$0.11 recorded in 2022.
- Peak annual rise in EPS (Weighted Average and Diluted) hit 150.0% in 2025, while the deepest fall reached 233.33% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.53 in 2021, then skyrocketed by 79.25% to -$0.11 in 2022, then skyrocketed by 54.55% to -$0.05 in 2023, then surged by 140.0% to $0.02 in 2024, then crashed by 150.0% to -$0.01 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for HRTX at -$0.01 in Q4 2025, -$0.1 in Q3 2025, and -$0.02 in Q2 2025.